Open AccessRoxadustat and thyroid-stimulating hormone suppression
Author(s) -
Atsuyuki Tokuyama,
Hiroyuki Kadoya,
Atsushi Obata,
Takahiro Obata,
Tatsuya Sasaki,
Naoki Kashihara
Publication year - 2021
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfab007
Subject(s) - medicine , levothyroxine , thyroid , triiodothyronine , hormone , endocrinology , hemodialysis , thyroid stimulating hormone , kidney disease
Hypoxia-inducible factor prolyl-hydroxylase inhibitors belong to a new class of orally administered drugs for treating anemia in patients with chronic kidney disease (CKD). The prevalence of hypothyroidism is disproportionately high in patients with CKD on hemodialysis. We report a rapid suppression of thyroid-stimulating hormone (TSH) and decrease in free triiodothyronine (T3) and free tetraiodothyronine levels after switching from darbepoetin alfa to roxadustat in a hemodialysis patient with hypothyroidism on levothyroxine therapy. This was reversed after stopping roxadustat. Roxadustat has structural similarity with T3 and is a selective activating ligand for thyroid hormone receptor-β possibly suppressing TSH release.